Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- The Rosen Law Firm PAROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRYWHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026.SO WHAT: If you purchased ARS Pharmaceuticals securities...
- Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the FirmKessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.
- Aizen TherapeuticsAizen Enters into Collaboration with San Diego Biopharma to Advance Oral BiologicsMulti-program deal with revenue potential of $100 million per target — Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to...
- Kleiman / RajaramKleiman Rajaram and Phillips & Cohen Announce Successful $46 Million Qui Tam Action Against Veloxis PharmaceuticalsVeloxis Admits to Kickbacks, and to Pay Criminal Fines and Civil Penalties — In a major healthcare fraud enforcement action, Veloxis Pharmaceuticals will pay over million and accept a stringent deferred prosecution agreement after admitting illegal...
- Kahn Swick & Foti, LLCCapricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NasdaqGS: CAPR) of a class action securities...
- Citizens Commission on Human Rights International Los AngelesCitizens Commission on Human Rights International Releases White Paper on Antidepressants and Psychiatric Drug ReformFederal deprescribing push and Florida’s new guidance underscore CCHR’s decades-long call to prevent misdiagnosis, harmful drugs, and needless suffering.
- Actinium Pharmaceuticals, Inc.Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing UpdateActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad...
- Neural Therapeutics Inc.Hanf.com Transaction Advances as Neural Therapeutics Receives CSE Conditional ApprovalNeural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of the Company's shares following completion of its previously announced fundamental change transaction involving CWE European Holdings Inc. ("CWE"), which operates the Hanf.com business in Germany (the "Series B Transactions"). Upon...
- Appili Therapeutics Inc.Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars unless otherwise stated."While ATI-1801 remains the Company's principal near-term...
- Optimi Health Establishes Discretionary Equity FacilityOptimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which the Company has the right, but not the obligation, to sell to Seven Knots up to US$100 million of its common shares from time to time over the term of the facility.
- Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSsCompanies: Jefferies Financial GroupMorgan StanleyLONDON, August 14, 2026--Silence Therapeutics plc, (Nasdaq: SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which incl
- PetVivo, a Leading Provider of Veterinary Biomedicals, Reports Results for Fiscal Q1 2027PetVivo Holdings, Inc. (OTCQX: PETV), in cooperation with its wholly owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, reported financial and operational results for the first quarter of its fiscal year ended June 30, 2026.